What's happening
This bill directs the health commissioner to study new opioid compounds found in overdose patients and recommend improved overdose treatment protocols.
Why it matters
Addresses the rise of novel and dangerous opioids. By focusing on new or previously unseen opioid compounds in overdose patients, the bill aims to ensure that public health responses keep pace with rapidly evolving drug trends, which traditional overdose treatments like Narcan may not fully address.
Emphasizes patient privacy and consent. The bill requires explicit, informed, and documented patient consent for sample collection, with strong protections ensuring samples cannot be used for law enforcement, probation, or other non-medical purposes—helping to build trust with overdose patients and encourage participation.
Prioritizes scientific rigor and statewide data. By mandating advanced laboratory analysis (e.g., LC-MS-MS and GC-MS) on randomly selected samples from every county, the study is likely to yield comprehensive, scientifically credible data on the spectrum of substances involved in overdoses across New York State.
Aims for actionable improvements in emergency care. The legislation requires the health commissioner to develop and publicly share new, evidence-based overdose treatment protocols, potentially leading to better outcomes for overdose patients, especially those affected by substances not responsive to standard treatments.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Study New Opioid Overdose Drugs
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Referred to rules
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Study New Opioids in Overdoses
In Assembly Committee · Health · Sponsor Brian Maher
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
9890
IN SENATE
August 16, 2024
Introduced by Sen. ROLISON -- read twice and ordered printed, and when printed to be committed to the Committee on Rules
AN ACT directing the commissioner of health to conduct a study to identify, analyze, report, and medically combat new or previously unseen opiate/opioid compounds found in overdose patients in New York state for the purpose of establishing more efficient overdose medical treatment protocols
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. This act shall be known and may be cited as the "identify dangerous drugs act (IDDA)".
§ 2. The opioid settlement fund advisory board, established pursuant to section 25.18 of the mental hygiene law, shall direct the commissioner of health to conduct a study of 250 random urine samples collected anonymously throughout the state of New York. Such samples shall: (i) represent each county in the state; (ii) be provided in accordance with HIPAA laws and regulations; and (iii) be identified by emergency room hospital physicians as having been generated from patients who, at the time of collection, were experiencing moderate to severe medical symptoms diagnosed as being directly related to an overdose associated from the use of an illicit unidentified opioid/opiate substance and/or combination of substances. Such urine samples shall:
(a) only be collected from patients diagnosed by an emergency room physician as experiencing moderate or severe overdose symptoms most likely related to opiate/opioid patient use;
(b) be collected by designated trained medical staff, including nurses, physicians, and physician assistants;
(c) be collected in tandem with the written and verbal consent of the patient and follow all designated HIPAA laws and regulations, including but not limited to identifying samples only by number on a form supplied to the hospital by the department of health. Such written consent shall be knowing and willful. The patient shall be verbally read conditions and forms by medical staff identified above and shall sign a document supplied by the department of health. Patients shall verbalize consent
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD11513-01-3
to the medical staff collecting the sample, as identified above, and shall be assessed by such staff as having full mental capacity as to consent to a legal document;
(d) be collected from a patient identified by the treating physician as experiencing current moderate to severe opiate/opioid overdose symptoms which may not have responded to emergency Narcan administration or the patient may be experiencing unusual or severe symptoms that the physician believes is related to opiate/opioid use, possibly in combination with other drugs. The treating physician must, in good faith, believe the patient is experiencing moderate to severe opiate/opioid related symptoms at the time the sample is collected and that such symptoms are from the use of illicit or non-prescribed medication or unintended use of prescribed medication in combination with an illicit drug.
§ 3. The samples collected pursuant to section two of this act shall be obtained only for the purpose of the study commissioned pursuant to section two of this act and shall not be accessed or reported for any other purpose including, but not limited to: use by law enforcement or the office of children and family services; consideration of probation or parole; or inclusion in the medical history of the patient. The study shall be conducted in good faith by all participating hospital staff and for the sole purpose of obtaining knowledge and information related to illicit opiate/opioid substance use.
§ 4. All samples collected, obtained, stored, and transported by physicians and emergency room staff should follow protocols established by the department of health. Such samples shall be sent to one designated laboratory with access to advanced chromatographic techniques, specifically liquid chromatography-tandem mass spectrometry (LC-MS-MS) and gas chromatography-mass spectrometry (GC-MS) to identify and measure a broad range of compounds, including new or unusual opiate analogs, xylazine or unidentified opiate/opioid compounds, combinations of illicit substances, and prescription medications.
§ 5. The study findings, data, results, treatment recommendations and suggested emergency room protocols shall be compiled into a report published by the commissioner of health which shall include recommended statewide treatment protocols and procedures. Such protocols and procedures shall take into consideration that the use of Narcan on patients with opiate/opioid overdose symptoms may not be sufficient for combatting a medical overdose emergency in a patient experiencing symptoms from new or unusual opiate analogs, xylazine or unidentified opiate/opioid compounds, commonly used combinations of illicit substances, or the unintended use of prescribed medication as found in the samples.
§ 6. Within one year from the effective date of this act, the commissioner of health shall submit the report required pursuant to section five of this act to the governor, the temporary president of the senate, the minority leader of the senate, the speaker of the assembly, the minority leader of the assembly, and the chairs and ranking members of the senate and assembly committees on health and shall post such report on the department of health's website. All hospitals and addiction treatment facilities shall be granted access to the report in a timely manner.
§ 7. The commissioner of health shall be authorized to promulgate rules and regulations to implement the provisions of this act.
§ 8. This act shall take effect immediately and shall expire and shall be deemed repealed thirty days after the delivery of the report to the governor and the legislature as provided for in section six of this act; provided that the commissioner of health shall notify the legislative bill drafting commission upon the occurrence of the delivery of the report provided for in section six of this act in order that the commission may maintain an accurate and timely effective data base of the official text of the laws of the state of New York in furtherance of effectuating the provisions of section 44 of the legislative law and section 70-b of the public officers law.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act directing the commissioner of health to conduct a study to iden- tify, analyze, report, and medically combat new or previously unseen opiate/opioid compounds found in overdose patients in New York state for the purpose of establishing more efficient overdose medical treatment protocols
Purpose or general idea of bill
Directs the commissioner of health to conduct a study to identify, analyze, report, and medically combat new or previously unseen opiate/ opioid compounds found in overdose patients in New York state
Summary of provisions
Section 1 - This Act shall be known and may be cited as the "identify dangerous drugs act (IDDA)"
Read the full memo (668 words)
Section 2 - The opioid settlement fund advisory board shall direct the commissioner of health to conduct a study of 250 random urine samples collected anonymously throughout the state of New York. Provides for who the samples shall be collected and from whom the samples will be collected.
Section 3 - The samples collected in this study shall be only used for the purposes of this study
Section 4 - All samples collected, obtained, stored, and transported should follow department of health protocols. Such samples shall be sent to a designated laboratory with access to advanced chromatographic tech- niques, specifically liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry.
Section 5 - The study findings, data, results, treatment recommendations and suggested emergency room protocols shall be compiled into a report published by the commissioner of health.
Section 6 - Within one year of the effective date the commissioner of health shall submit the report to the governor, the temporary p resident of the senate, the minority leader of the senate, the speaker of the assembly, the minority leader of the assembly, and the chairs and rank- ing members of the senate and assembly committees on health. As well as post such report on the department of health's website.
Section 7 - The commissioner of health shall be authorized to promulgate rules and regulations to implement the provisions of this ac
t.
Section 8 - This act shall,. Lake effect immediately and shall expire and be deemed repealed thirty days after the delivery of the report.
Justification
Hundreds of new deadly synthetic drugs have been introduced onto the streets of New York since 2009, yet the drug testing utilized in hospi- tals across the state is not capable of identifying the NPS (Novel Psychoactive Substances). Patients cannot be diagnosed and properly treated without knowing which drugs are in their system. The Identify Dangerous Drugs Act (IDDA) will commission a study about overdose patients receiving treatment in our hospitals. So that we can better understand and help solve this issue that plagues New York.
Since 2009, several new synthetic opioids including fentanyl and nitaz- enes have been introduced across New York State and the rest of the country. These deadly substances often lead to terrible consequences including thousands of deaths, addiction, and the destruction of fami- lies. Their continued use often leads to repeated theft and/or violence by people who suffer from addiction. Unless the new and commonly used opiate/opioid compounds, used in combination with other illicit substances, are identified and studied, the patients cannot be properly treated or given the proper antidotes to save their lives.
Emergency room or hospital-based toxicology labs do not have the neces- sary equipment, trained personnel or time to identify these new synthet- ic drugs and properly develop treatment protocols. Most hospitals only have the equipment designed to detect basic street drugs and cannot identify specific opiate analogs that cannot be combated by universal opiate-reversal drugs such as Narcan. Accordingly, comprehensive drug screening is expensive and generally not covered by insurance. As a result, many overdose patients do not receive medical treatment effec- tively targeting and combating their deadly symptoms related to the use of new or uncommon opiate/opioid analogs, additives or combinations of illicit drugs.
Prior legislative history
New Bill
Fiscal implications for state and local governments
To be determined
Effective date
Immediately
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.